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Abstract Pregnant women are usually excluded from
clinical trials. Physiologically based pharmacokinetic
(PBPK) modelling may provide a method to predict phar-
macokinetics in pregnant women, without the need to
perform extensive in vivo clinical trials. Here, we used
mechanistic modelling to delineate the potential impact of
drug transporters on darunavir pharmacokinetics and to
identify current knowledge gaps that limit accurate PBPK
modelling of darunavir/ritonavir (darunavir/r) exposure in
pregnancy. Simcyp (version 13.2) was used for PBPK
modelling, using physicochemical and in vitro pharma-
cokinetic parameters of darunavir and ritonavir from the
literature. The Michaelis–Menten constant (Km) and the
maximum rate of metabolite formation (Vmax) for cyto-
chrome P450 3A4-mediated darunavir biotransformation
and inhibition by ritonavir were determined experimen-
tally, while the contributions of hepatocyte influx and
efflux transporters were assessed by sensitivity analysis.
The simulations were compared with previously published
clinical pharmacokinetic data. We found that use of a well-
stirred liver model overestimated darunavir exposure sub-
stantially. A permeability-limited liver model, including
hepatic uptake and efflux transporters and an efficient
enterohepatic circulation step, resulted in an acceptable
description of darunavir/r exposure. For the 600/100 mg
darunavir/r twice-daily dose and the 800/100 mg once-
daily dose, the estimated pharmacokinetic parameters were
within a 2-fold range of the reported data. The predicted
decreases in the area under the concentration–time curve
(AUC) values during pregnancy for the twice- and once-
daily doses were 27 and 41 %, respectively, which were in
line with the observed decreases of 17–22 and 33 %. In
conclusion, our data support a clinically relevant role of
hepatic transporters in darunavir pharmacokinetics. By
including them in our model, we successfully approxi-
mated the increase in darunavir exposure mediated by
ritonavir co-administration and the decrease in darunavir
exposure observed during pregnancy.
Key Points
Our data support a clinically relevant role of hepatic
transporters in darunavir pharmacokinetics.
We successfully approximated the increase in
darunavir exposure mediated by ritonavir co-
administration and the decrease in darunavir
exposure during pregnancy, using physiologically
based pharmacokinetic modelling.
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1 Introduction
Pregnant women are generally excluded from clinical trials
during the development phase of new drugs, for obvious
ethical and safety reasons [1–3]. However, medication use
during pregnancy is not uncommon [4]. Most information
regarding safety, pharmacokinetics and placental transfer is
collected after drugs have become available on the market.
The implication of this is that pregnant women often use
medication for which the treating physicians have no
knowledge of the systemic drug exposure, the placental
transfer and hence the safety of the unborn child. On the
other hand, physicians may withhold beneficial medication
from pregnant women because they lack this critical infor-
mation. It would be a tremendous advantage if in silico
modelling could be applied to prediction of maternal and
fetal exposure of (new) drugs that are possibly being pre-
scribed during pregnancy. Such models would be particu-
larly relevant in the treatment of human immunodeficiency
virus (HIV). To prevent mother-to-child transmission,
pregnant HIV-infected women should use combination
antiretroviral treatment (cART) [5, 6]. Pregnancy-induced
reductions in maternal exposure to these drugs may lead to
subtherapeutic levels, eventually leading to virological
failure and/or resistance, thus requiring dose adjustment [7].
Physiologically based pharmacokinetic (PBPK) modelling
is a mechanistic approach to predict the absorption, distri-
bution, metabolism and excretion (ADME) of drugs on the
basis of the anatomy and physiology of the human body, as
well as physicochemical properties and in vitro data on
transport and biotransformation of the drug. In this way, the
handling of a drug by the body can be simulated, taking
molecular processes as a starting point. A PBPK model can
take into account the numerous physiological changes that
occur during pregnancy, affecting the volume of distribution,
plasma protein binding and metabolic clearance of drugs [8–
10]. In addition, PBPK modelling can allow quantitative
assessment of the impact of concomitantly prescribed inter-
acting drugs. This is particularly useful in HIV-infected
pregnant women, who typically use a cocktail of drugs, with
drug–drug interactions even being intentionally employed to
optimize treatment. For example, ritonavir, a strong cyto-
chrome P450 (CYP) 3A4 inhibitor, is used as a booster to
increase the exposure of antiretroviral drugs that are metab-
olized by CYP3A4. Finally, PBPK modelling provides an
effective manner to integrate the currently available mecha-
nistic drug disposition data and to obtain a better under-
standing of the pharmacokinetic behaviour of a compound.
Simcyp has developed a PBPK modelling platform,
which includes physiological changes in relation to the
duration of pregnancy (a p-PBPK model) [11, 12]. Expo-
sure to drugs during pregnancy at any gestational age may
be predicted, provided that in vitro pharmacokinetic data
on all processes relevant to drug disposition are avail-
able [11]. To study the feasibility of such a p-PBPK
modelling approach, we focused in this study on the
antiretroviral compound darunavir, co-administered with
ritonavir.
We developed and evaluated a mechanistic model to
predict darunavir exposure resulting from the treatment
regimens 600/100 mg darunavir/ritonavir (darunavir/r)
twice daily and 800/100 mg darunavir/r once daily, both
given with two nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) to provide a complete cART regimen.
These efforts also aimed to elucidate whether the appro-
priate in vitro pharmacokinetic parameters that are
required in such a model are currently available. Another
aim was to identify current knowledge gaps that limit the
accuracy of PBPK modelling of darunavir/r exposure,
thereby generating new hypotheses and hence directions
for future mechanistic studies to provide better under-
standing of darunavir/r disposition.
2 Methods
2.1 PBPK Modelling Platform
Simcyp Population-Based Pharmacokinetic Simulator ver-
sion 13 release 2 (Simcyp Limited, a Certara company,
Sheffield, UK) was used as a PBPK platform. [13–16]
Simulations were performed using Simcyp virtual popula-
tions of healthy volunteers and pregnant women. For each
simulation, the number of patients, gender, age range and
gestational age of the virtual population were matched with
clinical data sets used for validation.
2.2 Physicochemical and In Vitro Pharmacokinetic
Parameters of Darunavir
Darunavir physicochemical properties (e.g. molecular
weight, log P) and blood and protein binding properties
were obtained from the literature (Table 1). Holmstock
et al. [17] reported a 2.7-fold increase in darunavir
intestinal permeability (in mice and Caco-2 monolayers) of
darunavir in the presence of ritonavir, as a result of the
strong P-glycoprotein (P-gp) inhibitory effect of riton-
avir [17], which was in line with the findings of other
studies [18]. Therefore, when modelling the pharmacoki-
netics of darunavir alone, we used a reported in vitro Caco-
2 permeability of 7 9 10-6 cm s-1 for darunavir alone and
18.6 9 10-6 cm s-1 when simulating combined darunavir/
r administration. Darunavir is mainly eliminated by hepatic
metabolism; therefore, no renal clearance component was
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Table 1 Physicochemical and in vitro pharmacokinetic parameters of darunavir
Parameter Value References
Physicochemical
Molecular weight 548 g mol-1 Pubchem [52]
Log Po:w 1.8 http://www.antimicrobe.org/d94.asp (February
2015) [53]
http://www.drugbank.ca/drugs/db01264 (February
2015) [54]
Compound type Weak base
pKa http://www.drugbank.ca/drugs/db01264 (February
2015) [54]Strongest basic 2.39
Strongest acidic 13.59
Physiological charge 0
Blood:plasma ratio 0.64 EMA scientific discussion [19, 55]
Fraction unbound in plasma 0.06 EMA scientific discussion [19, 55]
Main plasma binding protein AAG EMA scientific discussion [19, 55]
Absorption
Absorption model ADAM
Permeability predicted via Caco-2
Apical pH:basolateral pH ratio 6.5:7.4
Activity Passive and active
Papp Caco-2 (10E-06 cm s
-1) 7 (in the absence of ritonavir) Holmstock et al. [17]
18.9 (in the presence of ritonavir) Holmstock et al. [17]
Scalar 1
Dosage form Immediate release, dissolution over 2-h period (fed
condition)
Available for reabsorption after biliary
excretion
Sensitivity analysis 0–100, 80 % was optimal
Distribution
Distribution model Full PBPK model
Predicted Vss (L h
-1) 1.23 Prediction method by Rodgers and Rowland [56]
Kp scalar 6 Empirically determined [19, 55]
Metabolism/elimination
Clearance type Enzyme kinetics
Test system Human liver microsomes
Enzyme kinetics CYP3A4 Vmax = 181 pmol min
-1 mg-1 microsomal protein Determined
Km = 1.1 lM Determined
Protein concentration = 0.25 mg mL-1 Determined
Fu,mic = 0.96 (pH 7.4) Calculated
Transport
Passive diffusion clearance 0.1 mL min-1 million cells-1 Simcyp default value
Pooled basolateral hepatocyte uptakea,
CLint,T
Sensitivity analysis 0–500 lL min-1 million cells-1
100 lL min-1 million cells-1 used in final model
Canalicular hepatocyte efflux (P-gp)
CLint,T
Sensitivity analysis 0–500 lL min-1 million cells-1
100 lL min-1 million cells-1 used in final model
ADAM advanced absorption and dissolution model, AAG a1-acid glycoprotein, CLint,T in vitro transporter-mediated intrinsic clearance, CYP cytochrome
P450, EMA European Medicines Agency, Fu,mic fraction of unbound drug in the in vitro microsomal incubation (calculated), Km Michaelis–Menten
constant, Kp partition coefficient, Papp permeability coefficient, PBPK physiologically based pharmacokinetic, P-gp P-glycoprotein, pKa acid dissociation
constant, Po:w Partition coefficient octanol:water, Vmax maximum rate of metabolite formation, Vss volume of distribution at steady state
a Reflecting various organic anion transporting polypeptides
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included in our simulations [19]. To determine the
Michaelis–Menten constant (Km) and the maximum rate of
metabolite formation (Vmax) for CYP3A4-mediated dar-
unavir metabolism, we performed in vitro tests using
human liver microsomes (HLMs) and baculosomes over-
expressing human recombinant CYP3A4. See the corre-
sponding paragraph below for a more detailed description
of these experiments.
For darunavir simulations, the Simcyp full PBPK dis-
tribution model was applied, which makes use of a number
of time-based differential equations in order to simulate the
concentrations in various organ compartments. Initially, we
used a well-stirred liver model without hepatic basolateral
uptake, canalicular excretion or intestinal reabsorption of
darunavir. In subsequent steps, modelling with a perme-
ability-limited liver model was performed, exploring vari-
ous degrees of hepatic uptake and efflux clearance, while
also addressing the impact of various efficiencies of
intestinal reuptake of the drug that was excreted unchanged
into bile. With respect to the modelling of enterohepatic
recycling, contraction of the gall bladder (resulting in
release of the drug into the duodenum) is included as a
periodic event corresponding to the Interdigestive Migrat-
ing Motor Complex (IMMC) cycle time and set at 1.55 h
(coefficient of variation [CV] 55 %). During contraction of
the gall bladder, release of the drug from the gallbladder
was defined by release constants of 0.18 h-1 (CV 30 %) in
the fasting state and 0.48 h-1 (CV 19 %) in the fed state.
2.3 Physicochemical, In Vitro and Clinical
Pharmacokinetic Parameters of Ritonavir
The ritonavir model used to simulate CYP3A4 and trans-
porter inhibition (boosting) was a semi-mechanistic phar-
macokinetic model, based on physicochemical parameters,
in vitro data and clinical pharmacokinetic data. Absorption
was based on first-order kinetics (absorption rate constant
[ka] = 0.24 h
-1 and fraction absorbed [fa] = 1) and a
volume of distribution at steady state (Vss) of 0.41 L kg
-1,
in line with data that has been derived from clinical stud-
ies [20]. Oral ritonavir clearance of the 100 mg dose is
16 L h-1 in healthy volunteers [21]. For the pregnant sit-
uation, a CL/F value of 20 L h-1 was used, as derived
from clinical observations [22, 23]. The interaction
potential of ritonavir was based on competitive inhibition
of CYP2C9, CYP2D6 and CYP3A4. We performed in vi-
tro tests in HLMs to corroborate and, if necessary, update
the ritonavir concentration producing 50 % inhibition
(IC50) on CYP3A4-mediated darunavir biotransformation
(see below). In addition to competitive inhibition, Fahmi
et al. [24] and Kaspera et al. [25] described mechanism-
based inhibition of CYP3A4 by ritonavir, which was also
included in the model. Inductive properties of ritonavir on
CYP3A4 have also been described and were added to the
model, on the basis of the work by Kirby et al. [26] We
included reported in vitro inhibitory potencies of ritonavir
on P-gp (hepatic canalicular efflux), as well as on the
pooled hepatic basolateral influx process, reflecting the
involvement of organic anion transporting polypeptides
(OATPs) in darunavir uptake. For the latter, we used the
reported IC50 of ritonavir on OATP1B3 (solute carrier
organic anion transporter family member 1B3
[SLCO1B3]) of 2.5 lM [27, 28].
2.4 In Vitro Testing
A range of darunavir concentrations (1–25 lM) was
incubated with HLMs and, at the end of the incubations,
final darunavir concentrations were determined by high-
performance liquid chromatography (HPLC) via a method
adapted from the protocol described by Droste et al. [29]
(lower limit of quantification: 50 nM or 0.027 mg L-1).
Incubations depleted darunavir concentrations on average
by 30 %. A prerequisite for conducting Michaelis–Menten
analysis is that no significant substrate depletion should
occur; however, it has been described that via this method,
a reasonable estimate of Km and Vmax can be still made,
which is suitable for our purposes [30]. The same protocol
was used to analyse the results obtained from incubations
with baculosomes overexpressing human recombinant
CYP3A4 (20 pmol mL-1), over a darunavir concentration
range of 1–10 lM. Enzyme-mediated darunavir biocon-
version was analysed by non-linear regression analysis
according to the Michaelis–Menten equation, using
GraphPad Prism 5 (version 5.02; GraphPad Software Inc.).
To determine the inhibitory effect of ritonavir on dar-
unavir biotransformation, incubations with HLMs were
performed as described above, in the presence of 1 lM
darunavir (substrate) and ritonavir (inhibitor) concentra-
tions ranging from 0.01 to 0.3 lM. The IC50 was estimated
by fitting a one-binding site inhibition model with a vari-
able slope to the data, using GraphPad. Derived IC50 values
from three separate experiments, each performed in
duplicate, were subsequently converted to a Ki value (the
binding affinity of the inhibitor) using the Cheng–Prusoff
equation (IC50/(1 ? [darunavir]/Km, darunavir)).
2.5 PBPK Workflow and Statistical Analysis
We first simulated the pharmacokinetics of darunavir in
healthy volunteers, when it was administered as a single
dose without ritonavir. We then verified the interactions of
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darunavir with ritonavir, first for a single dose of darunavir,
after Sekar et al. [31] and after Rittweger and Arasteh [19],
and then for the steady-state situation for the clinical dos-
ing regimens of 600/100 mg darunavir/r twice daily [32,
33] and 800/100 mg once daily. [34, 35] Before applica-
tion of the ritonavir semi-mechanistic model in the dar-
unavir PBPK modelling approach, the ritonavir model
performance was validated against data available from
interaction studies between ritonavir and midazolam (a
probe substrate for CYP3A4) [26, 36]. Acceptance criteria
were defined as follows: both the geometric mean maxi-
mum concentration (Cmax) and the area under the con-
centration–time curve (AUC) should not deviate more than
2-fold from the observed pharmacokinetic parameters, as is
commonly applied in assessing PBPK model performance.
After modelling of darunavir/r exposure in healthy volun-
teers, we proceeded to model darunavir/r pharmacokinetics
during pregnancy. Simulations of twice-daily 600/100 and
once-daily 800/100 darunavir/r were performed during the
second and third trimesters (the same gestational ages as
those reported in published clinical studies). For the non-
pregnant situation, simulations were performed using the
healthy volunteer population (females, matched for age
where reported). An independent-samples t test (SPSS 20)
was performed on the log-transformed AUCs, comparing
the pregnant situation with the non-pregnant situation,
resulting in geometric mean ratios (pregnant:non-pregnant)
and 90 % confidence intervals (CIs). Finally, we performed
simulations with higher darunavir/r dosages: 900/100 mg
darunavir/r once daily, as well as 800/100 and 900/100 mg
darunavir/r twice daily during pregnancy (in the third tri-
mester), to predict which dose would compensate for the
observed decrease in exposure. These dosages were chosen
because darunavir is available as 300, 400, 600 or 800 mg
film-coated tablets for oral use.
2.6 Comparison of Physiological Parameters
of the Simcyp Pregnant Population with
a Real-Life HIV-Infected Pregnant Population
Within a clinical study coordinated by our institution (the
Pharmacokinetics of Newly Developed Antiretroviral
Agents in HIV-Infected Pregnant Women [PANNA] study;
www.pannastudy.com), several physiological parameters
(the haematocrit and serum creatinine, a1-acid glycoprotein
[AAG] and albumin concentrations) were collected from
HIV-infected women during pregnancy and after delivery.
We compared these physiological parameters with those
used to define the Simcyp virtual healthy pregnant popula-
tion as described by Abduljalil et al. [10]. The data were
compared with the mean values summarized by Abduljalil
et al. to investigate if there were any differences between
HIV-infected and non-infected pregnant women, using an
independent-samples t test (SPSS 20).
3 Results
3.1 In Vitro Metabolic Clearance of Darunavir
A literature search yielded values for a substantial number
of mechanistic pharmacokinetic parameters related to
absorption and distribution of darunavir (Table 1). Because
quantitative data on in vitro darunavir metabolic clearance
by CYP enzymes (Km and Vmax values) were not available,
we determined the in vitro metabolic Km and Vmax using
HLMs.
Enzyme kinetics were determined at a protein concen-
tration of 0.25 mgmL-1 over a 30-min time period. We
found that darunavir bioconversion was saturable with
increasing concentrations (Fig. 1), characterized by a Km
value (95 % CI) of 1.1 (0.3–1.8) lM and a Vmax value
(95 % CI) of 180 (150–210) pmol min-1 mg-1 protein.
The Km value (95 % CI) derived from the experiments
performed in the baculosome CYP3A4-overexpression
system was 0.80 (0.17–1.43) lM (intrinsic metabolic
clearance [CLint,met] 2.25 lL min
-1 pmol-1 CYP3A4).
Fig. 1 Rate of darunavir disappearance (V) from human liver
microsomal incubations at increasing substrate concentrations. The
data represent a typical experiment; from a total of 3 experiments,
performed in duplicate, the mean ± range (minimum/maximum)
values are presented. A Michaelis–Menten equation was fitted to the
data as described in the ‘‘Methods’’ section. The calculated
Michaelis–Menten constant (Km) and the maximum rate of metabolite
formation (Vmax) for the indicated study are 1.1 lM and
180 pmol min-1 mg-1 microsomal protein
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3.2 Simulation of Darunavir Pharmacokinetics
Without Ritonavir
We simulated the concentration–time curve of a single oral
600 mg dose of darunavir in plasma with a well-stirred
liver model, hence assuming passive partitioning of the
drug from the plasma into the liver tissue, instantaneous
homogeneous distribution across the liver mass and
CYP3A4-mediated metabolic clearance as the only rele-
vant clearance mechanism. As can be seen in Fig. 2, the
simulations overestimated the total exposure of darunavir
when compared with the clinical data presented by Sekar
et al. [31] and by Rittweger and Arasteh [19].
3.3 Inclusion of Hepatic Influx and Efflux Transport
via Sensitivity Analyses
According to the general workflow of PBPK modelling and
simulation [12], we refined the model by taking clues from
in vitro pharmacokinetic studies as a starting point. Visual
Fig. 2 Simulation of darunavir plasma concentration (conc)–time
curves after a single oral dose of 600 mg, using the well-stirred liver
model on a linear scale (a) and on a semi-logarithmic scale (b). The
black circles represent the observed concentrations [19], the dashed
line represents the simulated mean concentrations and the dotted lines
represent the associated 95 % confidence intervals of the simulated
concentrations. The simulated plasma concentration data were
derived from 8 healthy subjects (3 female, 5 male) aged 27–37 years,
matching the subjects in the reported trial as far as possible
Fig. 3 Darunavir single-dose (600 mg oral) simulation of plasma
concentration (conc)–time curves at increasing intrinsic transport
clearance (CLint,T) uptake values (a) and CLint,T efflux values (b),
using the permeability-limited liver model. The black circles
represent the observed concentrations [19], the solid line reflects the
data obtained with the well-stirred liver model and the dashed lines
represent the simulated mean concentrations with application of the
permeability-limited liver model at increasing CLint,T values: 100,
200, 300, 400 and 500 lL min-1 million hepatocytes-1
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inspection of the curves indicated that the simulated
absorption phase was in line with the observed data. The
known interaction of darunavir with the basolateral
OATP1B1, 2B1, 1B3 and canalicular P-gp hepatocyte
membrane transporters [18, 28, 37] might influence dar-
unavir clearance. Therefore, we investigated whether
inclusion of a basolateral influx or a canalicular efflux
component in the model could improve the simulations.
The simulations performed for this sensitivity analysis are
reported in Supplementary Table 1. In Fig. 3, the effects of
different intrinsic uptake and efflux clearances on model fit
was examined. In Fig. 4, it can be seen that inclusion of
both a canalicular efflux and a basolateral uptake step
allows for better model fits at lower intrinsic transport
clearance values (CLint,T; lL min
-1million cells-1).
In vitro transport parameters (Km, Vmax or CLint,T) for
darunavir in human hepatocytes or recombinant overex-
pression systems of drug transporters were not available in
the literature. However, when uptake and efflux clearance
rates that have been measured for other drugs are consid-
ered, it can be seen that the required CLint,T values are in a
pharmacologically feasible range (Table 2). This is
Fig. 4 Darunavir single-dose (600 mg oral) simulation of plasma
concentration (conc)–time curves, assuming combined influx and
efflux processes, using the permeability-limited liver model (PMBL).
The black circles represent the observed concentrations [19], the solid
line reflects the data obtained with the well-stirred liver model
(WSLM) and the dashed line represents the simulated mean
concentrations with application of the PMBL with optimal CLint,T -
uptake/CLint,T efflux values of 100/100 lL min
-1million hepato-
cytes-1, respectively. CLint,T intrinsic transport clearance
Table 2 Intrinsic transport
clearance (CLint,T) influx and
efflux values reported in the
literature
Mean (SD)
Compound CLint,T uptake
[lL min-1 million cells-1]
CLint,T efflux
[lL min-1 million cells-1]
References
Bosentan 17.9 Me´nochet
et al. [44]
9.1 7.4 Jones et al. [43]
Cerivastatin 9.6 (2.7) 6.2 (1.8) Jones et al. [43]
Fluvastatin 45 (21) 17 Jones et al. [43]
Pitavastatin 40.7 Me´nochet
et al. [44]
Pravastatin 2.77 Me´nochet
et al. [44]
1.8 1.2 Jones et al. [43]
Repaglinide 79.0a Me´nochet
et al. [44]
30 (16) 0 Jones et al. [43]
Rosuvastatin 9.21 Me´nochet
et al. [44]
9.3 (2.6) 1.5 (0.088) Jones et al. [43]
Telmisartan 95.2a Me´nochet
et al. [44]
Valsartan 2.88 Me´nochet
et al. [44]
2.1 (0.5) 96a Jones et al. [43]
SD Standard deviation
Jones et al. [43] reported in vitro parameters estimated from sandwich culture human hepatocyte param-
eters at a single substrate concentration; mean from multiple replicates of 1–2 donors. Me´nochet et al. [44]
performed uptake kinetics in cryopreserved human hepatocytes at 7 concentrations; the uptake parameters
were estimated using a mechanistic 2-compartment model
a Reported parameter close to simulated estimate for darunavir
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particularly the case when combined hepatocellular influx
and efflux processes are assumed to take place.
3.4 Inhibitory Effect of Ritonavir on CYP3A4
In clinical practice, darunavir is always administered
together with ritonavir. In order to simulate this effect on a
mechanistic level, the ritonavir IC50 for inhibiting
CYP3A4-mediated darunavir metabolism is required. As
can be seen in Fig. 5, ritonavir completely inhibited dar-
unavir bioconversion, with an IC50 (95 % CI) of 0.06
(0.04–0.10) lM, which was equivalent to a mean Ki value
of 0.03 lM. This value was included in the ritonavir
model, together with other parameters listed in Table 3.
The performance of the ritonavir PBPK model was then
validated in simulations with midazolam, a probe substrate
for CYP3A4. Figure 6 presents the results of these simu-
lations, demonstrating that the model could predict the
increase in midazolam exposure within a 2-fold difference
of the reported clinical Cmax and AUC ratios.
3.5 Simulation of Combined Darunavir/Ritonavir
Administration
Next, simulations of the interaction of darunavir with
ritonavir were performed. First, the influence of ritonavir
on single-dose darunavir (600 mg) was simulated and
the data were compared with those reported by Rit-
tweger and Arasteh [19]. As can be seen in Fig. 7, a
strong increase in darunavir exposure could be simulated
when darunavir was combined with ritonavir, but only if
it was assumed that unchanged drug excreted via the
bile was readily available for enteric reabsorption.
Reducing the percentage available for reabsorption to
0 % abolished enterohepatic cycling, and the effect of
ritonavir was lost (see also Supplementary Table 1). In
contrast, it followed from our simulations that entero-
hepatic recirculation does not appear to be a major
player in determining exposure of single-dose darunavir
without ritonavir, as inclusion of the intestinal reab-
sorption of biliary-excreted darunavir was not necessary
to describe these clinical data (Fig. 7).
We also assessed whether the model predicted the
steady-state pharmacokinetics of relevant clinical dosage
regimens of 600/100 mg darunavir/r twice daily and
800/100 mg darunavir/r once daily [33–35, 38]. For this
situation, darunavir/r pharmacokinetics could also be sim-
ulated successfully with indicated CLint,T uptake, CLint,T
efflux and efficient enteric reuptake (80 %) values in place.
The simulated geometric mean darunavir AUC and Cmax
values were within a factor of 2 from the observed
parameters (Fig. 8).
3.6 Simulation of Darunavir and Ritonavir During
Pregnancy
With the same model, simulations for both regimens at
steady state were performed during the second and third
trimesters of pregnancy. Figures 9 and 10 show that the
prediction of the shape of the curves for both the non-
pregnant and pregnant situations was accurate. The
exposure was somewhat underestimated for the
800/100 mg darunavir/r once-daily dosing regimen. In
Table 4, the simulated pharmacokinetic parameters are
compared with the observed parameters from several
studies [22, 39]. The AUC decreases for the 600/100 mg
darunavir/r twice-daily dose were predicted to be 27
versus 24 % observed in the second trimester and 27 %
predicted versus 17–22 % observed in the third trimester.
For the 800/100 mg darunavir/r once-daily dose, a de-
crease in the AUC of 41 % was predicted versus an
observed decrease of 33 % in the third trimester. The
simulations with increased dosages are also described in
this table.
Fig. 5 Ritonavir inhibition of darunavir metabolism in human liver
microsomal preparations. The data represent the mean ± standard
error of the mean of three separate experiments, each performed in
duplicate. A 1-site binding model with a variable slope was fitted to
the data in order to estimate the ritonavir concentration producing
50 % inhibition (IC50). The calculated IC50 was 0.06 lM
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3.7 Physiological Parameters in the Simcyp Virtual
Population Library Versus a Real-Life HIV-
Infected Pregnant Population
Figure 11 shows the comparison of the haematocrit and the
serum creatinine, albumin and AAG concentrations
between HIV-infected and non-infected healthy pregnant
women (parameters used for the Simcyp p-PBPK
model) [10]. The haematocrit and the creatinine and
albumin concentrations were significantly lower in HIV-
infected women during pregnancy, but also postpartum.
The levels of the main darunavir binding protein in plasma,
AAG, did not differ between the two populations. Updating
the Simcyp model with the indicated parameters did not
significantly alter the simulation outcomes (data not
shown).
Table 3 Physicochemical and in vitro pharmacokinetic parameters of ritonavir
Parameter Value References
Physicochemical
Molecular weight 720.95 g mol-1 Pubchem [57]
Log Po:w 4.3 Simcyp compound library
Compound type Monoprotic base
pKa 2 Simcyp compound library
Blood:plasma ratio 0.587 Simcyp compound library
Fraction unbound in plasma 0.02 http://www.drugbank.ca/drugs/DB00503 [58]
Main plasma binding protein AGP
Absorption
Absorption model First-order absorption
Fraction absorbed 1 Simcyp compound library
ka (1 h
-1) 0.24 Simcyp compound library
Distribution
Distribution model Minimal PBPK model
Vss (L kg
-1) 0.41 Simcyp compound library
Metabolism/elimination
Clearance type In vivo clearance
CLpo (L h
-1) 16 non-pregnant; 20 pregnant Product characteristics Norvir [21], Colbers et al. [22]
CLr (L h
-1) 0.32
Interaction CYP
CYP2C9 Ki (lM) 4 (Fu,mic 0.29)
CYP2D6 Ki (lM) 10 (Fu,mic 0.29)
CYP3A4 Ki (lM) 0.03 (Fu,mic 0.976) Determined
CYP3A4 Kapp (lM) 0.1 (Fu,mic 0.91) Kaspera et al. [25]
CYP3A4 Kinact (1 h
-1) 0.32 (Fu,mic 0.91) Kaspera et al. [25]
Interaction transporters
ABCB1 (P-gp) Ki (lM) 0.2 (Fu,inc 0.233) Drewe et al. [27]
Pooled basolateral uptakea Ki (lM) 2.5 (Fu,inc 1) Annaert et al. [28]
AGP a1-acid glycoprotein, ABCB1 ATP-binding cassette, subfamily B, member 1, CLpo clearance after oral administration, CLr renal clear-
ance, CYP cytochrome P450, Fu,inc fraction of unbound drug in the in vitro hepatocyte incubation, Fu,mic fraction of unbound drug in the
in vitro microsomal incubation (calculated), ka absorption rate constant, Kapp concentration of mechanism-based inhibitor associated with half-
maximal inactivation rate, Ki concentration of inhibitor that supports half-maximal inhibition, Kinact inactivation rate of the enzyme,
PBPK physiologically based pharmacokinetic, P-gp P-glycoprotein, pKa acid dissociation constant, Po:w Partition coefficient octanol:water,
Vss volume of distribution at steady state
a Based on reported Ki for organic anion transporting polypeptide 1B3 (2.5 lM)
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4 Discussion
We developed and evaluated a mechanistic model to pre-
dict darunavir exposure, both in non-pregnant and in
pregnant women. Particularly, these efforts also focused on
elucidating the availability of crucial mechanistic in vitro
pharmacokinetic parameters that need to be incorporated
into such a model. Recently, Siccardi et al. [40] published
a paper on simulation of the pharmacokinetics of several
antiretrovirals co-administered with antidepressant drugs.
The pharmacokinetics of darunavir/r were also briefly
described in terms of a PBPK model, which included only
CYP3A4-mediated metabolism as a clearance mechanism.
However, our literature search (Table 1) revealed that
darunavir pharmacokinetics are known to be also deter-
mined by P-gp transport. Various in vitro studies have
demonstrated altered disposition of darunavir during co-
administration or co-incubation with P-gp inhibitors, one of
which is ritonavir [17]. Moreover, there is also possible
involvement of active hepatocellular uptake in the dispo-
sition of darunavir. In the rat, high concentrations of dar-
unavir were found in the liver [41]. This would be in line
with active hepatic uptake, which has been confirmed by
in vitro studies showing that darunavir can interact with
OATPs [28]. Therefore, we argued that an accurate PBPK
model describing darunavir/r should at least take into
account these active hepatic transport processes.
Only an accurate determination of metabolic clearance
could allow us to begin delineating to what extent uptake
and efflux transporters may be important to describe dar-
unavir pharmacokinetics mechanistically. Therefore, we
first conducted extensive studies on in vitro metabolic
darunavir clearance. The values we found were in the same
order of magnitude as the data described by Mamidi
et al. [42] and yielded similar metabolic intrinsic in vitro
clearances, i.e. 164 (in this study) versus 147 lL mg-1 -
min-1. The consistent overestimation of exposure with
only metabolic clearance in our models further underlined
the need to include drug transporters.
Fig. 6 Scatter plot representing the area under the plasma concen-
tration–time curve (AUC) ratio (AUCwith inhibitor/AUCwithout) values
of simulated and clinical drug-interaction studies between midazolam
and different ritonavir (RTV) doses, as reported by Katzenmaier
et al. [51], Kirby et al. [26] and Mathias et al. [36]. The dashed lines
represent a 2-fold difference from the observed values
Fig. 7 Linear plasma concentration (conc)–time curves (a) and semi-
logarithmic plasma concentration–time curves (b) for a single oral
dose of darunavir (600 mg) after 2 days of pre-treatment and in
combination with 100 mg ritonavir twice daily (black dashed lines),
or as a single oral dose of 600 mg darunavir alone (grey dashed line).
A permeability-limited liver model was simulated, with combined
influx and efflux processes taking place, both at a clearance rate of
100 lL min-1 million cells-1. For the darunavir/ritonavir simula-
tions, the response of the model to varying percentages of biliary-
excreted unchanged drug available for enteric reabsorption are
indicated (reflecting the maximum possible degree of enteric hepatic
recirculation). The black circles and grey circles are observed
concentrations taken from Rittweger and Arasteh [19]
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The well-stirred liver model performance could be
improved substantially when uptake and efflux transport
mechanisms were included against the background of a
permeability-limited liver model. Quantitative transport
kinetic data for darunavir are missing, but what is crucial in
our findings is that the simulation outcome improved with
CLint,T values in the range of what is found to be phar-
macologically feasible for liver uptake of other comparable
drug substrates [43, 44]. Nevertheless, our findings now
urge more detailed quantitative studies on darunavir
transport kinetics in cultures of hepatocytes or overex-
pression systems, in order to validate whether CLint,T,
uptake and CLint,T efflux values are in line with the values
that we predicted with our simulations. These studies
should also include measurements of membrane transporter
abundance to allow accurate extrapolation from in vitro to
in vivo. As the in vivo abundance of several hepatic
transporters has already been reported in the literature [45],
it is of particular relevance that new studies on the trans-
porter kinetics of darunavir should also include quantifi-
cation of absolute transporter expression in in vitro
incubation systems.
The ritonavir-mediated increase in darunavir exposure
could be adequately simulated if efficient enterohepatic
recycling was assumed, i.e. when 80–100 % of the dar-
unavir that was excreted unchanged via the bile was set to
be available for enteric reabsorption. Enterohepatic
circulation of darunavir has been suggested previ-
ously [46], but, to our knowledge, we are the first to cap-
ture this in a mechanistic model. However, for the
unboosted darunavir dose, inclusion of enterohepatic
cycling resulted in slightly overpredicted exposure. Possi-
bly, this discrepancy can be explained by unexpected non-
linearity in intestinal absorption at very low luminal dar-
unavir concentrations in the gut, resulting from biliary
Fig. 8 Scatter plot representing the area under the concentration–
time curve (AUC) and maximum concentration (Cmax) from simu-
lated and clinical darunavir/ritonavir (DRV/r) trials at steady state.
For the 600/100 mg darunavir/r twice-daily (BID) dose, two studies
by Sekar et al. [32, 33] were used, and for the 800/100 mg darunavir/
r once-daily (QD) dose, results reported by Boffito et al. [34] and
Kakuda et al. [35] were used. The dashed lines represent a 2-fold
difference from the observed values
Fig. 9 Simulation of darunavir plasma concentration (conc)–time
curves at steady state after 14 days of treatment with twice-daily
(BID) 600/100 mg darunavir/ritonavir (DRV/r) in the third trimester
of pregnancy (gestational week 36, n = 11, age 20–35 years) (a) and
in postpartum/non-pregnant subjects (n = 11, age 20–35 years) (b).
The black circles represent the observed concentrations [39], the solid
line represents the simulated mean concentrations and the dashed
lines represent the 95 % confidence interval of the simulated
concentrations
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excretion of darunavir. Low permeability could be due to
effective P-gp-mediated efflux of darunavir from entero-
cytes at these concentrations. This would indeed not be
expected in the presence of ritonavir, as this inhibits P-gp,
maintaining high darunavir permeability and effective
enterohepatic circulation even at very low concentrations.
Additional measurements of darunavir permeability in
Caco-2 cells, covering a wider/lower range of apical dar-
unavir concentrations, may reveal whether this effect does
indeed take place.
Pending the outcome of the proposed experiments to test
the hypotheses generated by the PBPK modelling work
described here, it is not possible to definitively separate the
contributions of uptake, efflux, metabolism and entero-
hepatic cycling to darunavir pharmacokinetics.
With regard to the data used for input into the ritonavir
model, it should be taken into account that mechanism-
based inhibition of ritonavir by definition also played a role
in the described HLM experiments, which were primarily
designed to assess the competitive aspect of CYP3A4
inhibition by ritonavir. This is virtually unavoidable, but, as
a result, the competitive CYP3A4 inhibitory component of
the ritonavir interaction model may have been slightly
overestimated. Despite this drawback, inclusion of the data
as an estimate of competitive CYP3A4 inhibition led to a
useful model, since the effect of ritonavir on midazolam
exposure was adequately predicted. An additional limita-
tion of the ritonavir model is that physiological changes in
pregnancy did not affect the ritonavir concentrations in the
current model, whereas in real life, this is the case [22, 39].
We compensated for this in our simulations by adjusting
the oral ritonavir clearance used for simulations in non-
pregnant individuals to reported values during pregnancy.
In general, a 50 % decrease in ritonavir exposure is
described in pregnancy, which could lead to a smaller
effect on darunavir exposure [22, 47]. However, clinical
studies have demonstrated that a 50 mg ritonavir dose also
increased darunavir concentrations almost as powerfully as
the 100 mg dose [48]. Therefore, we considered it unnec-
essary to develop a full mechanistic ritonavir PBPK model
on the basis of in vitro metabolic clearance parameters.
Future studies may address this in more detail.
As can be seen in Figs. 10 and 11, particularly for
800/100 mg darunavir/r once daily, the model overpre-
dicted the elimination rate. We hypothesize that a possible
explanation for the discrepancies between the observed and
simulated data is that the Simcyp pregnancy PBPK model
is based on physiological changes described for ‘healthy’
pregnant women, whereas the pregnancy pharmacokinetic
curves we used were taken from HIV-infected pregnant
women. The levels of the main darunavir binding protein
(AAG) did not differ between the two populations.
Although the haematocrit and albumin concentrations were
lower in the HIV-infected women, the effect of pregnancy
was similar for both physiological parameters. Anaemia,
with a decreased haematocrit, is common in HIV-infected
patients, as a result of the disease, or possibly resulting
from certain antiretroviral agents [49]. We do not expect
the decreased serum creatinine concentration at the end of
pregnancy, pointing to an increased glomerular filtration
rate, to be relevant for darunavir/r, as the renal clearance is
Fig. 10 Simulation of darunavir plasma concentration (conc)–time
curves at steady state after 14 days of treatment with once-daily (QD)
800/100 mg darunavir/ritonavir (DRV/r) in the third trimester of
pregnancy (gestational week 34, n = 16, age 20–44 years) (a) and in
postpartum/non-pregnant subjects (n = 8, age 20–44 years) (b). The
black circles represent the observed concentrations [22], the solid line
represents the simulated mean concentrations and the dashed lines
represent the 95 % confidence interval of the simulated
concentrations
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very low [41]. Nevertheless, our findings are important for
mechanistic pharmacokinetic modelling of other drugs that
are excreted renally, have high albumin binding or exhibit
high distribution into red blood cells.
Finally, we used the pregnancy PBPK model to predict
the alternative dose levels that may compensate for the
decreased exposure observed in pregnancy. It remains
questionable whether it is necessary to increase the dose
during pregnancy [22]. Nevertheless, two alternative
dosages (800/100 mg twice daily and 900/100 mg twice
daily), one of which was also predicted via our approach,
are indeed currently being investigated clinically in a
P1026 protocol by the International Maternal Pediatric
Adolescent AIDS Clinical Trials Group (IMPAACT)
group. The outcome will allow further validation of the
model described here [50]. Ultimately, PBPK model pre-
dictions may also be helpful in choosing the most optimal
dose in more complex cases—for example, when women
taking darunavir/r are not only pregnant but also use var-
ious medications that may additionally alter darunavir
pharmacokinetics via DDIs.
Table 4 Pharmacokinetic parameters of darunavir in pregnancy
Observed vs simulated AUC and Cmax values
95 % CI (SD)
Dosage, parameter and reference 2nd trimester 3rd trimester Postpartum GM ratio (90 % CI)
2nd trimester/postpartum 3rd trimester/postpartum
600/100 mg darunavir/ritonavir BID
AUC [mg h L-1]
Zorrilla et al. [39] 39 (10) 44 (16) 55 (27) 0.76 (0.63–0.90) 0.83 (0.72–0.97)
Colbers et al. [22] 41 (27–62) 53 (38–73) 0.78 (0.60–1.00)
Simulation 34 (25–46) 34 (26–45) 47 (36–61) 0.73 (0.51–1.02) 0.73 (0.53–1.02)
Cmax [mg L
-1]
Zorrilla et al. [39] 4.6 (1.1) 5.1 (0.5) 6.5 (2.4) 0.72 (0.61–0.86) 0.81 (0.69–0.96)
Colbers et al. [22] 5.0 (3.2–7.8) 6.5 (4.4–9.7) 0.76 (0.53–1.11)
Simulation 4.7 (3.7–6.1) 4.6 (3.7–5.8) 6.6 (5.3–8.3) 0.71 (0.53–0.96) 0.70 (0.53–0.93)
800/100 mg darunavir/ritonavir QD
AUC [mg h L-1]
Colbers et al. [22] 53 (44–63) 76 (65–90) 0.67 (0.56–0.82)
Simulation 29 (23–37) 49 (37–65) 0.59 (0.42–0.83)
Cmax [mg L
-1]
Colbers et al. [22] 5.3 (4.5–6.2) 6.8 (5.9–7.8) 0.78 (0.65–0.95)
Simulation 3.8 (3.3–4.5) 5.9 (4.7–7.5) 0.65 (0.51–0.82)
Simulations of increased doses in the 3rd trimester
Dosage AUC simulation Non-pregnant AUC GM ratio: 3rd trimester/non-pregnant (90 % CI)
BID QD BID QD
800/100 mg BID 44 (33–58) 47 (36–61) 0.93 (0.67–1.29)
900/100 mg BID 50 (38–66) 47 (36–61) 1.05 (0.76–1.47)
600/100 mg BID 9 2a 69 (53–90) 49 (37–65) 1.41 (1.00–1.98)
900/100 mg QD 39 (30–51) 49 (37–65) 0.80 (0.57–1.12)
AUC area under the plasma concentration–time curve, AUC0–xh AUC from 0 to x hours, BID twice daily, CI confidence interval, Cmax maxi-
mum concentration, GM geometric mean, QD once daily, SD standard deviation
a 600/100 mg AUC0–12h 9 2 to compare the AUC with the AUC0–24h
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5 Conclusion
A PBPK model that takes the involvement of hepatic drug
transporters and enterohepatic circulation into account
could adequately simulate darunavir/r pharmacokinetics
for several dosage regimens and patient populations. To
improve the mechanistic basis of the model, we propose
that future studies should address hepatic—but also
intestinal—transporter-mediated darunavir disposition in
more detail. The current model predicted decreased expo-
sure during pregnancy to be compensated for by
600/100 mg darunavir/r twice-daily dosing for women who
initially took the 800/100 mg darunavir/r once-daily dose.
For the 600/100 mg twice-daily dose (used in treatment-
experienced patients), the reduction in exposure can be
compensated for by an 800/100 mg darunavir/r twice-daily
dosing regimen.
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Fig. 11 Physiological parameters compared between healthy women
without human immunodeficiency virus (non HIV) and HIV-infected
pregnant women (HIV?). The data represent the mean ± standard
deviation per week of gestation for non HIV as reported [10] and for
HIV? women from the PANNA Network. Asterisk Significant
difference between HIV? and non HIV women (unrelated samples
t test). AAG a1-acid glycoprotein
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